Good day, and thank you for standing by. Welcome to the Bavarian Nordic Third Quarterly Report for the Nine-Month Period ended 30 September 2026. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star, one, and one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star, one, and one again. Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Anders Hjort, Head of Investor Relations. Please go ahead.
Thank you. Welcome to Bavarian Nordic's Q3 2026 results. Turning to slide number two, I assume you are all familiar with the forward-looking statement. If not, I suggest you become familiar with it. Turning to slide number three, just shortly in terms of the agenda for today that we will cover. First of all, we'll go through the key highlights, turning to Travel Health and Public Preparedness, a bit about the pipeline and our commercial performance. We'll finish up with the financial and the outlook for 2026, and of course, also the Q&A.
I'll now hand over the mic to the CEO, Tarja Stenvall.
Thank you, Anders. Good morning and good afternoon, everyone, and a warm welcome also from my side. This is my first earnings call for Bavarian Nordic, and I'm very pleased that we can report another quarter of strong performance, providing a really solid foundation for Bavarian Nordic's next chapter. Before going into the numbers, let me share shortly some of my first thoughts as a new CEO. First of all, I am very excited to have joined Bavarian Nordic, and I look forward to leading the company into the next phase of growth. I'm also looking forward to getting to know all of you on these calls and through our wider investor engagement. Many of you may already be familiar with my background and what you can expect from me.
Having served close to 30 years in large global pharmaceutical companies, including leading a vaccines business, my focus has been on growing and transforming businesses, building long-term partnerships with governments, health authorities, and importantly, making clear choices about where to invest and grow. I've now been with Bavarian Nordic for about a month, and naturally, I am still in the listening and learning phase. I spend much of the time with our teams at our sites, with our partners, key stakeholders, but this has left me already with some observations. Firstly, I see speed and agility driven by purpose. People here solve problems without waiting for direction. They have a sense of urgency driven by shared purpose of making life-saving vaccines available to more people. Secondly, I see a delivery under pressure with a real learning culture.
Challenges surface early, and there's a strong appetite to keep improving. They are really hungry to learn. Then finally, but very importantly, I see as well deep expertise and trusted relationships. We have deep knowledge of infectious diseases and a strong network with governments and public authorities we work with. This trust have obviously been built over many years, and I do see it as a real asset to build on. Bavarian Nordic has a good foundation and an encouraging momentum to build on. Together with our leadership team and the board, we've started to identify the key questions we need to explore in depth over the coming months to sharpen our strategy, such as, how do we fully capture the growth potential in Travel Health, especially in rabies and the Vimkunya launch, and strengthen our position in the key markets such as the U.S.?
How do we deepen our partnerships with governments to build greater long-term predictability in Public Preparedness? Then with demand clearly growing strongly, how do we build a manufacturing and supply network that supports our growth efficiently and competitively? Then how do we build on our vaccine expertise and platforms to scale the business, both organically and through business development and acquisitions? The objective is simple, to make clear choices about where we focus our efforts and investments to create long-term value. We will share our strategic priorities in the first half of 2027, including our approach to capital allocation. In the meantime, we remain fully focused on keeping our momentum and delivering on our commitments. Then turning to the Q3 results. For the first nine months, revenue was just under DKK 4.9 billion, representing reported growth of 2%.
Adjusting for the discontinued partnerships and foreign exchange, organic growth was over 9%. EBITDA margin was exceptionally strong, close to 35%, also reflecting the phasing of R&D and commercial investments in Q4. Travel Health grew 22% in the third quarter and 24% in the first nine months. If we exclude discontinued partnerships, growth was over 30%. The main driver is continued momentum in rabies, especially in the U.S., but across geographies, supported by the ongoing launch of Vimkunya and the rest of the portfolio. Public Preparedness is in line with our expectations and remains above our annual base level. We've secured around DKK 2.4 billion for 2026 and secured around DKK 900 million for 2027. That includes our new four-year contract with the U.K. government, a really good example of the longer-term partnerships we want to build.
Our financial position is strong. We completed the first tranche of our share buyback in October, and we're starting a second tranche of up to DKK 150 million today. We're maintaining our 2026 outlook, revenue of around DKK 6.1 billion, including approximately DKK 4 billion from Travel Health, and an EBITDA margin of around 32%. In summary, Q2 was another quarter of strong performance, reflecting the strength of our business, solid execution, and our continued ability to deliver on our commitments. I want to recognize the dedication and efforts of our team across Bavarian Nordic, whose contributions have been instrumental in delivering these results.
With this overview, I will hand over to Henrik, our CFO, who will take you through the performance and the business in more detail. As you have heard or actually read in the announcement this morning, Henrik has taken a decision to step down as our CFO this coming spring. We've initiated a search, and I'm confident we can do a smooth transition. Although Henrik is not going anytime soon, I already want to recognize his big contribution for Bavarian Nordic, and also on my onboarding, that is, of course, still ongoing.
Henrik, please.
Yeah. No, thank you very much, Tarja. Good to have you here at your first earnings call, really. Let's not spend too much time on my situation. This is about the quarter, but I can only say there's absolutely no drama involved with my desire to step down as a CFO. Absolutely not. It's done in a good manner, and I'm sure we will secure some good handover and transition to my successor and to Tarja as well. Let's focus on the quarter this time here. As Tarja said, very strong numbers we have just reported this morning here. I will spend a little time on the next slides here, looking at first our Travel Health business and then Public Preparedness after that.
Let's start with Travel Health that demonstrated extremely high growth numbers, 32% for the quarter and 34% for the nine months if we adjust for the discontinued partner business we used to have with Valneva and Dynavax. So very, very strong growth. To a large extent driven by a continued strong momentum within our rabies business, but also supported by the continued launch of Vimkunya, our chikungunya vaccine, and actually also by TBE when we look at TBE on a nine-month basis. If we dive into the rabies business, then we have seen continued very, very strong market growth across markets, but in particularly outspoken in the U.S. market, which we have seen growing by 36% first nine months compared to prior year. And here you need to understand that it has actually been an accelerating growth.
In the beginning of the year, we saw closer to the 20% growth year-over-year, but that has right now, on a monthly basis, has accelerated up to around 50% growth. But on a nine-month basis, 36% growth on the rabies business. So very, very strong market demands. I will come back to on one of the next slides in a moment what really drives that. That has, of course, as we are the market leader, that market growth has a significant impact on our revenue, and we deliver 39% revenue growth on a nine-month basis. U.S. explained a lot of it, as I said, but we also see significant growth in several European markets, and we start to see the markets we took back from Valneva actually also contributing to the growth of our rabies business.
If we then turn to tick-borne encephalitis, our Encepur vaccine, we have to acknowledge that this year has been a challenging year for our TBE business. We entered the year with relatively low shelf life, which made it a real challenge for our commercial organization to sell into wholesalers and distributors. We have since managed to increase the shelf life. We are not fully home yet, and we continue to work to increase the shelf life. That has caused periods with supply constraints, and it has caused quarters with disruption. But we are very, very happy that when we look at this business on a year-to-date basis, we have actually delivered a 9% growth. Due to a tremendous effort by our commercial organization, we have maintained our market share.
It's obvious that when we look at the quarter by quarter, we have seen positive quarters, and now in the third quarter here, we actually saw negative growth due to some of the challenges we are facing. But over the year, 9% growth. I think we can be very happy with that given the situation we were in. We are right now leaving the TBE season, and our issues should hopefully be resolved, or they are resolved right now, so that we are ready to enter into the next season starting spring next year. Let's spend a little more time on rabies as it explains so much of our growth at the moment. If we turn to the next slide to talk a little about the underlying growth drivers for the continued strong growth of the rabies market.
Here, let's focus on the U.S., which is the key contributor to the growth. I think what we are seeing right now in the U.S. is that rabies is endemic in the U.S., and the areas where you see increased rabies activities are just expanding. That is evidenced by some of the monitoring that the U.S. CDC is doing. Several hotspots have been identified in the U.S. in different states with elevated rabies activity. It has also been seen that the rabies is spreading to more animal species. It used to be mainly bats, but now it's also other types of animals as well. That combined with people spending a lot of time outdoor, gives a lot of many more situations that you usually have with human to animal encounters, and that drives what we call the exposure vaccinations.
When people are in contact with rabid animals in the nature, you have to immediately go to the emergency clinic and get vaccinated. As this is a deadly disease, there's a lot of media attention around these statistics, and that again, that media attention creates a demand for vaccinations ahead of any risks. That is the pre-exposure segment of the market that is therefore also seeing a quite significant increase. So very, very strong demand driven by the endemic situation in the U.S. at the moment. We get a lot of questions around, is this a sustainable situation we see or what's going to happen going forward? I think first of all, I think we have to be honest and say it's a difficult market to forecast in, as not only is the market increasing, the growth in itself has been accelerating.
We are, of course, looking into how we can forecast this better going forward. But as we sit here right now, we see no signs that the market should decline again. We are dealing with animals that are infected by rabies in the nature, so it is much more difficult to control than an outbreak in human people that you can actually vaccinate. So far, no signs that the market should suddenly decline again. Let us turn to the next slide, which talks about one of our other growth drivers. That is our chikungunya vaccine, Vimkunya, which we have now launched in most of Europe and in the U.S. as well. I think we have on a nine-month basis, we have now delivered DKK 151 million. As you will recall, we are targeting DKK 200 million for the full year.
We have seen so far very good performance in several European markets. Germany in particular has actually exceeded our expectations. I think where we are still challenged is in the U.S. market, where we, to be honest, we are not living up to our own expectations yet. But what we have seen is the U.S. taking a rather conservative approach to the recommendation, and at the same time, the recommendation from ACIP has not yet been confirmed in the MMWR publication. It does give us some short-term headwinds still in the U.S. to be resolved. We are though quite confident that the U.S. will eventually become one of our key markets also for this product here. This is a disease, chikungunya, that is just in its infancy, if you ask us. We have seen even last week, we saw local transmission of this disease in Switzerland.
The mosquito that is spreading this type of disease is spreading to many more territories, and therefore, we do believe that there is a very significant future potential in this area. Turning to the next slide, and let us talk about the other business leg we have, our Public Preparedness business. We have in the third quarter, we have delivered on the orders that we have secured already, so performance in line with our expectations, approximately DKK 1.9 billion. We are targeting DKK 2.5 billion for the full year, and we have already secured DKK 2.4 billion of those by contract. We need still to close a small gap in terms of contracting, but we are very confident that that is going to happen as well.
Remember, when we entered the year, we regarded this year to be a more normalized year with no mpox impact as we saw in the three to four previous years, and therefore, we lowered our expectations to this year. But despite that, we have managed to get some good large contracts, enabling us to deliver DKK 2.5 billion this year, which is above our normal business base level of DKK 1.5 billion-DKK 2 billion. Again, strong execution on Public Preparedness. We are very happy that we earlier this year managed to, in Europe, to extend the label to include children age two to 12, and we have some more ongoing trials that will eventually help us to further expand the label for this vaccine.
On the next two slides, I just wanted to share a couple of recent developments within our Public Preparedness business. And I think on the first one here, we talk about the initiative taken by the International Coordinating Group on Vaccine Provision, which is hosted by the WHO. They have taken an initiative to create a global emergency stockpile that in particularly lower middle income countries can tap into. And we are very proud that we were awarded a contract to supply 150,000 doses into this stockpile. And on top of that, we decided to donate another 75,000 doses of our vaccine. This will all be delivered this year into the stockpile so that the ICG, the International Coordinating Group, can allocate these according to the needs. A very, very good development, securing vaccine access to low and middle-income countries.
On the next slide, another good development. We have recently announced that we were awarded a contract with the U.K. government. The very interesting thing with this contract is that it is a multi-year contract. It is a four-year contract to supply mpox, smallpox vaccine to the U.K. government. We do not have many of those, and it has been the cause of some of the volatility we have seen in our Public Preparedness business in the past has been that governments typically would not commit beyond one year. This is a very good sign of our long-standing partnership with the U.K. government. Enough about the commercial business. Then a very quick update on our pipeline, which you will see on the page now.
Overall, all our programs, they are on track. We are running post-approval committed studies on chikungunya. We are developing the cell line manufacturing process for our MVA smallpox/mpox vaccine, which is now running in phase II. And we are also in phase II with an equine encephalitis vaccine development fully funded by the U.S. government. And then we do have two preclinical assets, Lyme assets, where we anticipate to go into the clinic in 2028, and then our EBV preclinical assets, which we still believe should enter the clinic this year. All in all, in line with plans, and hopefully that the two preclinical assets are going to generate an interesting news flow going forward as well.
Now let us turn to some of the financials, and we will start with the commercial performance. And as Tarja alluded to, she did highlight some of the numbers here. If you just look at the reported numbers for the quarter, it says 0.6% growth, but if we adjust for discontinued partnership, it is actually more than 9% for the quarter, 7% full year. But more interestingly, it is to look at the individual business legs where we saw Travel Health growing 32% when adjusted for third-party products, and 34% on a nine-month basis. Strong growth from our travel business and solid execution on our Public Preparedness business.
I have already addressed some of these, the rabies business, 38% growth. Encepur, 9% growth, despite the challenges that we have been facing. Vimkunya, 258%. It is obviously a new launch. So all in all, very strong growth. We also saw Vivotif growing strongly. Vaxchora, small product that is typically driven more by outbreaks and specific orders. So all in all, on a nine-month basis, nearly DKK 4.8 billion. So let us turn to the full P&L. We already touched upon the top line. If we then turn to the gross profit, we delivered 52% for the quarter. It is up a couple of percentage points compared to last year, driven by a good product and country mix. If you look into the quarter in itself, there were things contributing positively, and that is definitely product and country mix.
A lot more sales into the U.S. and a lot more rabies sales. But then on the more challenging front, we also had some challenges when we changed from TBE campaign manufacturing first half of this year, and during the summer, we were switching over to rabies. That changeover took longer than anticipated, which meant that basically we couldn't manufacture for three to four weeks, and that, of course, also has an impact on the gross margin. But it is all, you can say, absorbed within the numbers that you see here, and still we come out with quite a solid gross margin here.
We are right now up and running with rabies, according to the plans again. Total operating costs, somewhat below last year's level for the quarter, mainly explained by some of the initial Vimkunya launch costs that were included in the third quarter of last year, and also some costs associated with the takeover attempt last year as well. If we take it all down to the bottom line, we see we are delivering an extraordinary 34.4% EBITDA margin, very strong EBITDA margin. Also above, you can say, the stated ambition level of 25%-30% that we have announced previously. When we compare to last year, we have to remember that in the Q3 of last year, we sold a priority review voucher, which gave us DKK 810 million in income.
If you deduct that from the EBITDA, then you're actually comparing to a 28% EBITDA last year. We are up 6% in terms of profitability as well. On a nine-month basis, also close to 35% EBITDA and an EBITDA of DKK 1.7 billion. So very, very strong performance on the P&L this year. Next slide deals with the cash flow. Of course, strong EBITDA typically means you're also delivering a strong cash flow. If we look at the quarter in itself, it was DKK 809 million cash flow from operating activities. Cash flow from investment activities, these are mainly placement of cash into securities, so really not as such consuming the cash, giving us a free cash flow of more than DKK 500 million.
The cash flow from financing activities, the DKK 170 million, that's all explained more or less by the share buyback programs we've done during the quarter. Still, after the share buybacks, we are delivering net cash flow of DKK 372 million. So very, very strong cash flow generation as well. If you look at the cash flow for the nine months, you have to remember that during that period of time, we paid back the last milestone to GSK, EUR 70 million, which is impacting the cash flow from operating activities. If you obviously deduct from that, you will also see that it's a very strong performance for the full nine months.
Final page, I will just use that one to remind you of our current outlook for the year. We are, after upgrading both our Public Preparedness business and our Travel Health business, we are now projecting DKK 6.1 billion in revenue, DKK 3.4 billion from our Travel Health business and DKK 2.5 billion from Public Preparedness, and we are targeting an EBITDA for the full year of 32%.
With that, I will give the word back to the operator and ask for questions, please.
Thank you. To ask a question, you will need to press star, one, and one on your telephone and wait for your name to be announced. To withdraw your question, please press star, one, and one again. One moment for our first question. This one comes from Thomas Bowers from SEB. Please go ahead.
Yes, thank you very much. A few questions from me here. Maybe just to kick off with your 2026 guidance. Can you maybe comment a little bit on the implied Q4 revenue outlook? Travel Health revenue approximately, well, DKK 500 million ±. That implies a decline of 20% or maybe 10% if you adjust for the partner product sale. What actually explains this implied slowdown, also given that maybe Encepur should maybe recover a little bit at least?
Then on Vimkunya, sales very strong this quarter with, I guess, almost double there quarter-on-quarter. I understand Germany is appearing to be the key driver here. Can you maybe just explain sort of the differences between or across Europe on the uptake and maybe how we should think about the pace of that market development in Europe going forward?
Then just the last question, just on capacity. Exceptional Rabipur demand obviously, but I am a little bit curious on manufacturing capacity. Will that still be sufficient if you continue that strong growth going into 2027, also without compromising any TBE supply here, or any need for additional investment to increase that production capability, I guess? Thank you.
Okay. To start, Henrik, will you take the first question?
Sure, I will do that. Thank you, Thomas, for the questions here. Let me address the first one on the guidance. I think first of all, don't forget what our guidance says approximately, and we are guiding DKK 3.4 billion on Travel Health. There can, of course, be variations to that. It is an approximate guidance. Then don't forget the seasonality as well. If you look at the EBITDA margin and the Q4 there, I think the reason for that is that we are targeting a lower EBITDA margin for the Q4 in itself, is first of all expected lower revenue compared to the previous nine months. That's implied from our guidance, obviously, but then also backend loaded investments into R&D projects and sales and marketing.
I think we can fairly say that we are probably on the conservative side, but nothing that should require that we should change our guidance at this point in time. I hope that was sufficient on that one, Thomas.
Yeah, thank you.
Maybe I say few words on Vimkunya. You asked specifically about Europe. They are saying about the U.S., and Henrik highlighted that we have some access topics at the moment. Still, I think it is important. It is a disease in infancy in the U.S. as well, so we continue working hard as well in terms of raising awareness, making sure that the safety profile of our vaccine is well known as well, knowing that there was a vaccine that was withdrawn from the market. When it comes to Europe, obviously Germany, as often is the kind of number one market in Europe, and we put our efforts there, and we are very pleased how we see the takeoff in terms of travelers and the doctors adapting the vaccine, as well as working markets around.
We also start seeing cases of chikungunya. I think the other week we heard that there was a case in south of France, for example. So I think the disease, even in Europe, it is in infancy at the moment. As usual, in launch, we go a bit step by step, and we are learning as we are moving forward. But we are very pleased in terms of how we see the progress in Europe at the moment. I do not know, Henrik, if you have?
Yeah. No, maybe I can just add one thing, and that is when you look at the quarterly numbers on Vimkunya, do not expect a smooth curve, because we are launching in so many countries, and therefore it can be a little lumpy when you supply into the whole supply chain. It will probably not be a smooth curve one day when we look back on how we entered this market here. But as we sit here right now, today, we are confident that we will meet the soft guidance we have provided of DKK 200 million.
Yeah. And of course, U.S. plays important role in the Europe business.
Yeah.
Does that answer?
Yes. Then there was one on capacity.
Yeah, if, yeah. Then the capacity, I would also say that, looking at the organization, we have been able to really deliver well on this growing demand. U.S., we have had no supply issues this year at all. We have done quick wins as well smartly. I call it quick wins in manufacturing to really keep up with it. Obviously, being a life-saving vaccine, and us playing such an important role with the high market share in many countries, that is a real priority for us going forward. Making sure with the forecast for the future that we have the right manufacturing and supply capabilities that can work effectively and deliver. We have to estimate and see with the demand then what type of investments we need to put into that place.
Then the question about Encepur and Rabipur. Well, maybe you want to elaborate on this one as well, Henrik.
Yeah. I think you explained it pretty well, Tarja. I think what we have done right now is that we have done everything we can in terms of easy wins. We did during the summer break here, we changed the batch sizes. We are going to do that again during the Christmas shutdown. I think we are quite confident that that will enable us to supply into expected demand during 2027. But of course, we are constantly looking at this, and as we talked about it before, we need really to understand where this rabies market in the U.S. is going, and then it might require additional investments that are not the quick wins, but we might need to also invest to make sure we can, even the years beyond 2027, we can still supply to the demand in the market, as this is a life-saving vaccine.
Perfect. Thank you very much.
Thank you. We are now going to take the next question. This one comes from Romy O'Connor from Kempen. Please go ahead.
Hello. Thank you for taking our questions, and thank you for the presentation. I also had one on Vimkunya. With the U.S. uptake expectedly slower, I was just wondering if you can clarify a bit more on what the conservative approach you mentioned meant from the CDC. Regarding timelines for the MMWR publication, what could the 2027 ramp then look like if that would not happen? Maybe more of a general question. With the second tranche of the buyback underway, and also the strong cash position, I was just wondering what we should expect to learn about how you will weigh investments in the existing portfolio, maybe potential M&A and further buybacks in the strategic presentation in the next half of 2027. Thank you.
Thank you. Yeah.
Thank you. Do you want to elaborate a bit on the U.S. side, then I can talk about the investments?
Yes. So thanks, Romy. What I mentioned regarding the conservative approach by the U.S. government on the recommendation is, there is currently a recommendation in the U.S. that if you travel to a country with a current outbreak, you should get vaccinated. The conservatism comes in, but how do you determine a current outbreak? In the U.S., that is defined by a U.S. citizen coming back to the U.S. with chikungunya, which is very, very late in the process. What it actually means that if you look up on the CDC's website today, there are only three countries listed with current outbreaks. The similar European side, I believe there are more than 15 countries listed, because here they actually monitor ongoing real outbreaks. It is a rather conservative definition of an outbreak in the U.S.
Then, of course, combined with the fact that they have not yet confirmed the ACIP recommendation in the MMWR publication, that is normally more of an administrative task. It does not mean we cannot sell, but it means that some of the customers are reluctant to buy because they are breaking sort of their normal routines. They normally look up in the MMWR to find the recommendations, and if they cannot, they say, "Okay, then we are not buying." So it is just providing a short-term headwind to us. We do believe that this is something that will over time be resolved. It will take time, of course, to work with the government.
We know that U.S. is one of the markets where you do now and then have outbreaks of chikungunya as well, and we think that will eventually also convince people of the need to have a vaccine available in the market and to have a good recommendation in place. That was the question on Vimkunya. Then we have the question on the buybacks, and you are right, we are doing buybacks at the moment. Sorry, there is some noise in the background. I do not know how it comes in here. Okay, I will continue. We are right now, as we have reported, we just finished the first tranche of the DKK 750 million buyback, and we this morning announced the start of the next. We are in a very, very solid financial position.
We have reported, despite the share buybacks, nearly DKK 3 billion of cash. We have plenty of cash at the moment. If you look in our R&D, you talked a little about investing in our current portfolio and inorganically as well. Part of our money really goes into what we call lifecycle management, to make sure that we improve the position of all our products, and a lot of that is really some of the label expansion opportunities we have to make sure that our products are covering as broad as possible in the market. That is one of the areas where we invest. Then we have the M&A part, which remains part of our strategy, and we are constantly looking at opportunities, but we are also extremely picky.
We only want something that is generating revenue, that is our current focus at least, that is generating revenue from day one, is not diluting our profitability, and that fits in with our commercial infrastructure. We have decided that right now, we are striking a good balance between preserving cash to act on opportunities when the right ones are there, and then paying money back to the shareholders with the current share buybacks.
Then maybe to build on Henrik's answer, at the moment, we are working, in this moment, is a good momentum to take a look at the opportunities that we have, I would say, a lot around us. Where do we stand by investing our current business, and how can we make that grow and get the full potential out of it? Then also look at M&A at the same time. We are planning to come out then in the next spring with the guidance in terms of capital allocation going forward.
Yes.
Very clear. Thank you.
Thank you. We are now going to take the next question. This one is from Håkon Hemme from Danske Bank. Please go ahead.
Great. Thank you for taking my questions. Tarja, welcome and congratulations on the new role. A couple of questions from my side. On rabies, at the Q2 call, you explained that the wholesaler inventory buildup had amplified growth. Your Q3 sales are now up 37%, both quarter-over-quarter and year-over-year, as you mentioned. While your commentary now seems more focused on underlying demand, can you elaborate on that? Was the Q3 performance purely driven by underlying demand, or did the wholesaler inventory movements also contribute?
Just to follow up on M&A, because you say that you are constantly looking at M&A, but with you, Tarja, now in the role and Henrik preparing to leave, are you still actively pursuing M&A opportunities in this transition period, or has it become less of a priority until a full team is ready? Thank you.
Yeah. Let me take the rabies one. I think what we said during the Q2, as you are right, Håkon, thanks for the question, by the way. We did say that the wholesaler inventory probably amplified the growth, and I think what is happening when a market is growing as fast as we are seeing here with rabies, as we talked to earlier, in beginning of the year, we saw 20% growth, but it has actually been accelerating up to 50% growth. Then what is happening at the wholesaler level, they typically try to have a certain number of days on inventory, so they constantly also increase their holdings, amplifying the whole situation.
That happened during Q2. It probably also happened here during Q3. That is simply just an effect of such a rapid increase. It is difficult for us to separate the effects really, because we are talking two different numbers. The market growth that we are looking at with close to 40% on the nine month, that is in-market data. There is a time lag to ours, and we, of course, record what we sell into the wholesalers. But I think this amplification is simply an effect of such increased demand. As wholesalers, they typically define their inventory levels as days of sales compared to expected future sales.
I think that was on the rabies. Then we had the M&A, Tarja.
M&A questions. Yeah. So I would say yes, M&A continues to be part of our strategy, as it has been in the past year. I would say it has been in the DNA of Bavarian Nordic. The whole Travel business has been built on the M&A. When I then talk about sharpening the strategy going forward and next year, we gave our last guidance, 2024 longer-term guidance. I think it is a good momentum right now with sales that are exceeding expectations to do a little bit sit back and make sure that we are truly focused on the right priorities to be able to drive existing business in terms of targets for M&A activity as well. Then more about that in the next year. But yes, it is, continues to be part of our strategy.
Got it. Thank you.
Thank you.
Thank you. We're going to take the next question. This one is from Peter Hugreffe from Nordea. Please go ahead.
Yeah. Hi, Peter Hugreffe from Nordea. Thank you so much for taking my questions, and again, also welcome to you, Tarja. Two questions. Firstly, I can see that you are quoted in Danish media that you are talking about a strategic change, which of course is interesting. Can you maybe give us a little bit of comfort around this strategy review? What is the direction? What is it that you're looking for? That's the first question. Secondly, your predecessor, one of the last things he did was to up the Public Preparedness outlook from DKK 1.5 billion- DKK 2 billion, to actually DKK 2 billion. Now I can see that either it's forgotten or you have retracted on that part. Is it DKK 2 billion as a base, or are we back to DKK 1.5 billion-DKK 2 billion? Thank you so much.
Well, thank you, Peter, and thanks for welcoming me to my new role. I go back on your question about this strategy. I think we're doing well. I said it's a very strong and solid base to continue the business. When you grow with the speed and change that Bavarian Nordic has done, they created another business besides the MVA-BN WEV platform. You can see that there's many things ongoing, and people are committed. They take a lot of action. I think it's a good way to make sure we channel the energy exactly to the right place.
That's why I'm calling sharpening the strategy, make sure that we really focus on the right priorities under existing business, as well as looking at the M&A opportunities, so that we really scale the platform in terms of growing that platform, that we can then absorb more growth, either organically or inorganically. We have a very young commercial organization still. It has been there only a few years. It is also making sure that in that side, we focus on what matters the most in terms of understanding the markets, focusing in the markets that are the most critical going forward.
I do not know if that gives you a clear view, Peter, what I meant by that.
Yeah. For me, it sounds more like you are focusing on how can you execute on your strategy rather than a review of the current, but maybe it is semantics.
Yeah, maybe it is semantics. I think you need to take holistically each sector of our business. There is the Public Preparedness, there is the business of Travel Health, and then you look at the M&A side. So you look at holistically these three pillars, and you make it clear on the direction going forward.
Got it.
Great. Thanks, Peter, for the questions here. To the other one on Public Preparedness, we have not officially changed our guidance on that one, so our medium-term guidance. It remains DKK 1.5 billion-DKK 2 billion. I think what Paul said is that looking at what we have achieved so far, I think he said we are probably closer to the DKK 2 billion, but we have not officially changed that one. I think this year is a good example. We are delivering DKK 2.5 billion, so that could argue, of course, we are going above the DKK 1.5 billion- DKK 2 billion, but it is also still very sensitive to few big orders.
Next year, as Tarja alluded to, we will come out with a sharpened strategy, and end of next year, our midterm financial targets are also sort of expiring, which we announced at the Capital Markets Day in 2024. In connection with that, it would be natural to sort of also restate what is the base business level for Public Preparedness. So far, it stays at the DKK 1.5 billion-DKK 2 billion, but we are very happy that even this year, in a year where there is no material impacts, we are delivering DKK 2.5 billion, so significantly above that base business level.
Got it. Can I have a follow-up on the Public Preparedness?
Sure.
It is just when I compare with where we are today compared with last year, then you have secured DKK 900 million, and last year it was DKK 1.1 billion. I mean, is it fair to assume that you are almost kind of at the same level for 2027, based on what you see right now? Or is there any kind of lumpiness in what you have secured already now compared to last year? Just trying to understand kind of the trajectory. Does that make sense?
No, I think it is fair. I think if you asked us two months ago, we would probably say we are ahead of last year. But if you look at it right now, we are probably more or less same place as we were this time last year, with DKK 900 million, I would not say in the bank, but at least orders secured. We feel that we are in a good position also to deliver within the ambition level for next year.
Okay. Got it. Good. Thank you.
Thank you.
Thank you. We are now going to take the next question. This one is from Benjamin Jackson from Jefferies. Please go ahead.
Great. Thank you for the question. Just one for me this time. I am just interested to know whether you have any color you can provide on how European rabies market would react to a new entrant in that market. Obviously, one of your competitors hoping for approval towards the end of this year. How do we think about the spillover of that on either price or volumes to you guys? Is there anything else worth flagging about contracting timelines, et cetera? Any thoughts around that would be super useful. Thank you.
Well, thank you. Thank you, Benjamin, for the question. What I have seen so far, I think our rabies position in key markets is really strong if I look at the U.S. and Germany. We have been a good partner in terms of supply constantly, and the vaccine has been market for a long time with the very, very strong data. In terms of the competitor and what they can offer, I think we are in a very good position to keep the leadership and the strong position in the market going forward. At the moment as well, it is a growing market. Our job as well is to make sure that we increase the awareness and make sure that people would get vaccinated as they should going forward. Does that answer your question, Benjamin?
Yes, I guess to some extent. Thank you.
Thank you. There are no further questions for today. I will now hand the call back to Tarja Stenvall for closing remarks.
Well, thank you everyone for attending the call and for your questions and for welcoming me as well. With this, I hope you as well a very nice weekend. Thank you.
Thank you. This concludes today's conference call. Thank you for participating. You may now disconnect.